Effect of adacolumn and adalimumab combination therapy for the active stage Crohn's disease
Not Applicable
- Conditions
- Crohn's disease
- Registration Number
- JPRN-UMIN000007047
- Lead Sponsor
- Yamaguchi University Graduate School of Medicine Department of Gastroenterology and Hepatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Below 2,000 / mm3 granulocyte count Severe infection Severe heart disease Severe Renal disease Systolic blood pressure less than 80mmHg patient with suspected or currently pregnant Increased intensity of extreme dehydration or coagulation system Severe anemia Malignant tumor Short-bowel syndrome Artificial anus External fistula Ileus or svere stenosis of the intestine Extraintestinal complications Recent use of steroid, 5-Aminosalicylic acid, immunomodulator, biologics, elemental diet Recent operation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Remission induction rate 11 weeks after the start of therapy. Remission rate 104 weeks after the start of therapy.
- Secondary Outcome Measures
Name Time Method Remission period CT or CT enteroclysis/enterography Change of the CRP Safety